Focused On-demand Library for Complement factor B

Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.


We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Reaxense helps in synthesizing and delivering these compounds.


The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.


Our high-tech, dedicated method is applied to construct targeted libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

It includes comprehensive molecular simulations of the catalytic and allosteric binding pockets and the ensemble virtual screening accounting for their conformational mobility. In the case of designing modulators, the structural changes induced by reaction intermediates are taken into account to leverage activity and selectivity.


Key features that set our library apart include:


  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.

  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.

  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.

  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.

PARTNER
Receptor.AI
 
UPACC
P00751

UPID:
CFAB_HUMAN

ALTERNATIVE NAMES:
C3/C5 convertase; Glycine-rich beta glycoprotein; PBF2; Properdin factor B

ALTERNATIVE UPACC:
P00751; B0QZQ6; O15006; Q29944; Q53F89; Q5JP67; Q5ST50; Q96HX6; Q9BTF5; Q9BX92

BACKGROUND:
The protein Complement factor B, known for its alternative names such as Glycine-rich beta glycoprotein, plays a pivotal role in the immune system's alternative complement pathway. It is essential for the cleavage of factor D into fragments Ba and Bb, where Bb combines with complement factor 3b to form the C3 or C5 convertase, crucial for immune defense mechanisms.

THERAPEUTIC SIGNIFICANCE:
Understanding the role of Complement factor B could open doors to potential therapeutic strategies. Its involvement in critical diseases like age-related macular degeneration and atypical hemolytic uremic syndrome underscores its significance in developing treatments for immune-related conditions.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.


Page 8486 of 8789